Feiyiliu Mixture sensitizes EGFRDel19/T790M/C797S mutant non-small cell lung cancer to osimertinib by attenuating the PRC1/Wnt/EGFR pathway
Introduction: Osimertinib is a potent epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for the treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC). However, the emergence of acquired resistance due to the EGFR-Del19/T790M/C797S mutation limits the clinical...
Bewaard in:
Hoofdauteurs: | , , , , |
---|---|
Formaat: | Boek |
Gepubliceerd in: |
Frontiers Media S.A.,
2023-01-01T00:00:00Z.
|
Onderwerpen: | |
Online toegang: | Connect to this object online. |
Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|
Internet
Connect to this object online.3rd Floor Main Library
Plaatsingsnummer: |
A1234.567 |
---|---|
Kopie 1 | Beschikbaar |